A melanocortin receptor agonist approved in the U.S. for acquired, generalized HSDD in premenopausal women under defined label conditions. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICPT-141 / Bremelanotide
LibidoSexual WellnessNeuroendocrine
Status
Approved
Related
2
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
PUBLISHED STUDY
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYObstetrics & Gynecology, 2019Verified 2026-09-13
Bremelanotide acts through melanocortin receptors in the central nervous system. Its evidence and approval are explicitly women-specific and indication-specific.
Mechanism summaries are stored with field-level source provenance for editorial audit.
05
Women in the research
FEMALE REPRESENTATION100.0%1267 of 1267 participants
DOSE STRUCTURENot reportedNo separate “women’s dose” was defined.
SEX-SPECIFIC FINDINGSReported as an exploratory subgroupThe two phase 3 trials enrolled premenopausal women and reported female sexual desire, related distress and adverse events; 1,247 were included in the safety population.
Premenopausal women with acquired, generalized HSDD.